BRIEF-Abbvie receives U.S. FDA approval of supplemental new drug application for Viekira Pak without Ribavirin
April 25, 2016 at 11:30 AM EDT
* Abbvie receives u.s. Fda approval of supplemental new drug application for viekira pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without ribavirin in genotype 1b chronic hepatitis c patients with compensated cirrhosis